Steven R. Gerbsman, Principal of Gerbsman Partners and Kenneth Hardesty, CEO-in-Residence at Gerbsman Partners, announced today their success in maximizing stakeholder value for a leading provider of comprehensive cardiac safety assessment for clinical trials.

Gerbsman Partners facilitated the sale of the business, its associated Intellectual Property and assets. Due to market conditions, the venture capital-backed company made the strategic decision to maximize the value of the business and Intellectual Property and conduct an orderly wind down of remaining operations. Gerbsman Partners provided leadership to the company with:

• Crisis Management experience in developing the strategic action plans for maximizing value of the business, its Intellectual Property and assets;
• The ability to "Manage the Process" among Clients, potential Acquirers, Lawyers, Creditors, Management and Stakeholders;
• The proven ability to "Drive" toward successful closure for all parties at interest and provide for an orderly shut down of operations.

About Gerbsman Partners

Gerbsman Partners focuses on maximizing enterprise value for stakeholders and shareholders in under-performing, under-capitalized and under-valued companies and their Intellectual Property, as well as assisting Mobile 2.0 companies with strategic alliances, M&A, distribution of content and licensing.

In the past 60 months, Gerbsman Partners has been involved in maximizing value for 33 Technology and Life Science companies and their Intellectual Property and has restructured/terminated over $720 million of real estate executory contracts and equipment lease/sub-debt obligations. Since inception, Gerbsman Partners has been involved in over $2.1 billion of financings, restructurings and M&A transactions.

Gerbsman Partners has offices and strategic alliances in North America, Europe and Israel.